Postconfluent multilayered cell line cultures for selective screening of gemcitabine.

The in vitro cytotoxicity of gemcitabine (dFdC) was tested in ovarian and colon cancer cell lines grown as monolayers and three-dimensional multilayered cell cultures. In our model, dFdC showed slight selectivity in cytotoxicity against ovarian over colon cancer cells, when cell lines were grown as monolayers. However, when cell lines were grown as multilayers, this selectivity was accentuated: A2780 multilayers were 14 times less sensitive than monolayers, but the colon cancer cell lines were more than 1000 times more resistant than their corresponding monolayers. The accumulation of the active metabolite, dFdCTP, after 24 h exposure to 1 microM dFdC varied between 1100 and 1900 pmol/10(6) cells in monolayers. This was 5 times lower in multilayers compared with monolayers of all four cell lines, which can, in part, explain the lower sensitivity of the multilayers. In addition, it appears that the amount of the active metabolite retained is more important than the amount accumulated initially, since the differences between the ovarian and the colon cancer cell lines were more evident in retention experiments. Exposure to dFdC caused a 2-3-fold increase in the levels of several nucleotides, except for the CTP pools in the colon cancer lines, which were reduced by 3-fold at the highest dFdC concentration (10 microM). The findings with the multilayer model are in better agreement with in vivo activity in ovarian cancer and colon cancer than those with the monolayer system. This indicates the potential of the multilayer system to be a better predictive model than the conventionally used monolayer cultures.

[1]  H. Pinedo,et al.  Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. , 1996, Biochemical pharmacology.

[2]  Benjamin Rs Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[3]  G. Peters,et al.  Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. , 1992, British Journal of Cancer.

[4]  S. Kaye Gemcitabine: current status of phase I and II trials. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Plunkett,et al.  Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. , 1990, Cancer research.

[6]  W. Plunkett,et al.  Preclinical characteristics of gemcitabine , 1995, Anti-cancer drugs.

[7]  V. Heinemann,et al.  2′,2′-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells , 1989 .

[8]  G. Peters,et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.

[9]  Kenneth D. Paull,et al.  Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen , 1992 .

[10]  G. Peters,et al.  Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.

[11]  T. Lawrence,et al.  Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. , 1994, Cancer research.

[12]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[13]  G. Peters,et al.  Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.

[14]  J. Neijt,et al.  Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients , 1995, Anti-cancer drugs.

[15]  H. Pinedo,et al.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. , 1993, British Journal of Cancer.

[16]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[17]  V. Heinemann,et al.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation. , 1995, Seminars in oncology.

[18]  G. Peters,et al.  Gemcitabine: Future Prospects of Single-Agent and Combination Studies. , 1997, The oncologist.

[19]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[20]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[21]  Laurence H. Baker,et al.  Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development , 1992, Developments in Oncology.

[22]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[23]  G. Peters,et al.  Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. , 1994, Biochemical pharmacology.

[24]  G. Peters,et al.  Introduction: Gemcitabine - Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog , 1995 .

[25]  Y Z Xu,et al.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.

[26]  H. Preisler,et al.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy. , 1979, Cancer research.

[27]  G. Snow,et al.  Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. , 1991, Cancer research.

[28]  G. Peters,et al.  Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. , 1993, European journal of cancer.

[29]  H. Hansen,et al.  Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). , 1993, Cancer treatment reviews.

[30]  G. Peters,et al.  Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. , 1994, Biochemical pharmacology.